A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the ...

In this interview, Vernon Sondak, MD, the chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Florida, explains the latest approach to treating ...

A new report shows better than 80% concordance between liquid biopsy and tissue biopsy. Liquid biopsy and analysis of circulating tumor DNA (ctDNA) is a viable option for determining the presence of ...

Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news. The recent approval by the ...

A final discussion point is real-world applicability. Although PHAROS presents exceptional PFS, the modest difference between ...

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- Dual ...

SAN FRANCISCO -- First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer (mCRC), according to the BREAKWATER ...

Ojemda is the first FDA-approved systemic therapy for pediatric LGG patients with BRAF rearrangements, including fusions. The Food and Drug Administration (FDA) has granted accelerated approval to ...